2010
DOI: 10.1158/1535-7163.mct-09-1217
|View full text |Cite
|
Sign up to set email alerts
|

Erythropoietin and Ovarian Cancer – Response

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2011
2011
2019
2019

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 7 publications
0
2
0
Order By: Relevance
“…The acquired resistance of A2780cis cells was maintained by supplementation of media with 1 µM of cisplatin every second passage. 22 Cell viability assay. A2780 and A2780cis cells were seeded into 96-well culture plates at a concentration of 3×10 3 and 6×10 3 cells per well, respectively.…”
Section: Cellular Studiesmentioning
confidence: 99%
“…The acquired resistance of A2780cis cells was maintained by supplementation of media with 1 µM of cisplatin every second passage. 22 Cell viability assay. A2780 and A2780cis cells were seeded into 96-well culture plates at a concentration of 3×10 3 and 6×10 3 cells per well, respectively.…”
Section: Cellular Studiesmentioning
confidence: 99%
“…Cisplatin-based chemotherapy is a primary treatment for ovarian cancer. However, the resistance to cisplatin remains a major obstacle in the effective treatment of ovarian cancers [1][2][3][4]. Deactivating cisplatin -resistant ovarian cells is an urgent task.…”
Section: Introductionmentioning
confidence: 99%